{"title":"HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00973-0","DOIUrl":null,"url":null,"abstract":"<p>Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.</p><p>In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"188 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00973-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.
In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
